Fig. 2

Anti-BAFF is present in a subset of pediatric SLE patients with active disease. a Recombinant BAFF was used to coat 96-well ELISA plates, and sera from 45 pSLE patients and 24 age-matched healthy controls were used to probe them in triplicate. HRP-conjugated goat anti-human IgG (heavy and light chain) was used as a secondary reagent. After development with TMB substrate, absorbance was measured at 450 nm, and each sample is shown as a percentage of the maximum absorbance. b The pSLE patients were divided into groups based on their serum reactivity to BAFF. The modified SELENA-SLEDAI is shown for the lowest quartile (Low, <5.8), middle two quartiles (Int), and highest quartile (High, >11.0). Mann–Whitney tests were used to compare reactivity between groups (bars show mean ± SEM). BAFF B cell-activating factor, ELISA enzyme-linked immunosorbent assay, IgG immunoglobulin G, HRP horseradish peroxidase, pSLE pediatric systemic lupus erythematosus, SELENA-SLEDAI Safety of Estrogen in Lupus Erythematosus National Assessment-SLE disease activity index, SLE systemic lupus erythematosus, TMB 3,3′,5,5′-tetramethylbenzidine